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Background: Tanshinone IIA (TIIA) is a diterpene quinone extracted from the plant Danshen (Salvia miltiorrhiza)
used in traditional Chinese herbal medicine. It has been reported to have anti-tumor potential against several kinds
of cancer, including gastric cancer. In most solid tumors, a metabolic switch to glucose is a hallmark of cancer cells,
which do this to provide nutrients for cell proliferation. However, the mechanism associated with glucose metabolism
by which TIIA acts on gastric cancer cells remains to be elucidated.
Results: We found that TIIA treatment is able to significantly inhibit cell growth and the proliferation of gastric cancer
in a dose-dependent manner. Using next-generation sequencing-based RNA-seq transcriptomics and quantitative
proteomics-isobaric tags for relative and absolute quantification (iTRAQ), we characterized the mechanism of TIIA
regulation in gastric cancer cell line AGS. In total, 16,603 unique transcripts and 102 proteins were identified.
After enrichment analysis, we found that TIIA regulated genes are involved in carbohydrate metabolism, the cell
cycle, apoptosis, DNA damage and cytoskeleton reorganization. Our proteomics data revealed the downregulation
of intracellular ATP levels, glucose-6-phosphate isomerase and L-lactate dehydrogenase B chains by TIIA, which
might work with disorders of glucose metabolism and extracellular lactate levels to suppress cell proliferation.
The up-regulation of p53 and down-regulation of AKT was shown in TIIA- treated cells, which indicates the
transformation of oncogenes. Severe DNA damage, cell cycle arrest at the G2/M transition and apoptosis with
cytoskeleton reorganization were detected in TIIA-treated gastric cancer cells.
Conclusions: Combining transcriptomics and proteomics results, we propose that TIIA treatment could lead
cell stresses, including nutrient deficiency and DNA damage, by inhibiting the glucose metabolism of cancer
cells. This study provides an insight into how the TIIA regulatory metabolism in gastric cancer cells suppresses
cell growth, and may help improve the development of cancer therapy.
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unless otherwise stated.worldwide in 2008 [1]. However, anti-cancer drug devel-
opment of gastric cancer today remains slow and costly,
and drug-resistance remains a potential obstacle [2].
Tanshinone IIA (TIIA) is a diterpene quinone extracted
from the plant Danshen (Salvia miltiorrhiza), which is
used in traditional Chinese medicine [3]. The first usage
of Danshen extractions as herbal medicine can be traced
back to more than 1800 years ago [4]. Its applications in-
clude prevention of cardiac diseases [5], protection of the
nervous system [6] and hepatocytes [7], and inhibition of
osteoporosis [8]. Drug repositioning is considered to be a
promising and valuable method for the reduction of thes is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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velopment. The functions of many chemicals extracted
from Danshen are therefore explored for their anti-cancer
potential, and TIIA is the most abundant and structurally
representative of these [9]. TIIA has been recently re-
ported to have anti-cancer potential against several can-
cers including breast cancer [10], prostate cancer [11],
colorectal cancer [12], lung cancer [13], liver cancer [14],
leukemia [15], and gastric cancer [16]. However, the regu-
latory mechanism of TIIA in gastric cancer cells remains
unclear.
Metabolic transformation accompanying nutritional
imbalance is one of the leading causes of cancer pro-
gression. Glucose is a primary source for the pentose
phosphate pathway, which makes RNA and DNA. Glyco-
lytic intermediates can be used to assist lipid biosynthesis
to produce ATP and non-essential amino acids, such as
alanine, for growth [17]. Proliferating cells are commonly
maintained by enhancing aerobic glycolysis, also called
the Warburg effect, which causes lactate accumulation
and contributes to the development of malignancies. In
oncogenic pathways, phosphatidylinositide 3-kinases (PI3K)/
protein kinase B (AKT) has been shown to enhance gly-
colysis, while the tumor suppressor p53 inhibits it, sug-
gesting a glycolytic switch intrinsically associated with
oncogenic transformation [18]. Through the inference of
oncogene expression and glucose metabolism, the supply
of nutrients to cancer cells could be blocked, which would
stunt their proliferative potential. This may be an import-
ant finding for drug discovery.
High-throughput data can be used to provide a com-
prehensive inventory of all the biological processes of
cells, display their complexity, and increase data accur-
acy. An accurate picture of the differential expression of
experimental samples is important for defining precise
targets and networks. Here we use two types of high-
throughput data to uncover the regulatory mechanism
of TIIA in gastric cancer cells: transcription levels from
next-generation sequencing (NGS) data, and isobaric
tags for relative and absolute quantification (iTRAQ)-
based quantitative proteomics analysis. NGS is one of
newer transcriptome sequencing approaches and can
perform high-throughput sequencing by generating
thousands or millions of sequences in parallel [19]. It has
better sensitivity and lower background noise than
microarray analysis, and more researchers are using
it to investigate the mechanisms of anti-cancer drugs
[19,20]. iTRAQ is a promising new technique for quan-
titative proteomics which can quantify proteins from
different sources using their different tags [21]. Because
of its sensitivity in labeling peptides, it is considered
a more powerful quantitative proteomic technique
than others, including the two frequently used quanti-
tative proteomics techniques 2D-DIGE (difference gelelectrophoresis) and cICAT (cleavable isotope-coded
affinity tags) [22,23].
In this study, we identified a total of 16,603 unique tran-
scripts and 102 TIIA-regulated proteins that are involved
in glucose metabolic process. We further investigated and
found that TIIA blocks glycolysis and gluconeogenesis in
cancer cells by altering protein expression, and causes
DNA damage, cell cycle arrest, cytoskeleton reorganization
and apoptosis.
Results
TIIA reduces the growth rate and suppresses proliferation
of gastric cancer AGS cells
To determine whether TIIA can affect gastric cancer cell
survival, we treated AGS cells with different concentra-
tions to detect real-time cell growth rates by an RTCA
(Real-Time Cell Analyzer; xCELLigence™; Roche Applied
Science & ACEA Biosciences) system. The IC50 of TIIA
at 48 hr was calculated to be 5.3 μM. Figure 1A shows
that 0.1 μM TIIA was only slightly effective, whereas
10 μM TIIA killed almost all cells. Each curve is signifi-
cantly different from the other (p < 0.0001, Wilcoxon
Signed-Rank Test). Our results demonstrate that the cell
growth rate was significantly decreased under TIIA
treatment conditions compared with controls, suggesting
that AGS cell growth was significantly inhibited by TIIA
in a dose-dependent manner.
To explore whether TIIA could affect gastric cancer
cell proliferation rates, we treated AGS cells at different
concentrations of TIIA and counted the number of cell
colonies stained with crystal violet. The results show that
0.53 μM (1/10 IC50) TIIA reduces colonies to about
60%, whereas 5.3 μM (IC50) TIIA results in almost no
colonies. It indicates that the proliferation rate of AGS
cells was significantly suppressed by TIIA in a dose-
dependent manner (*p < 0.05, **p < 0.01, Student’s t-test)
(Figure 1B and C).
Functional annotation enrichment of TIIA -regulated genes
To uncover the TIIA regulatory mechanism in AGS cells,
we performed RNA-seq analysis to profile the transcrip-
tomes of gastric cancer cells when treated with dimethyl
sulfoxide (DMSO) (control) or with TIIA. In order to
characterize the gene expression profile to response of
biological functions, our initial analysis performed func-
tional enrichment of all identified genes onto MetaCore
pathway analysis. Major bio-functional networks were
significantly enriched and showed in Figure 2A. Of six
bio-functional networks, “Catabolic process” is top-ranked.
Previous studies have shown that dysregulation of metab-
olism is an important indicator for tumorgenesis [17].
Thus, we forced on metabolic networks to enrich all iden-
tified genes by MetaCore. As indicated in Figure 2B, a
large number of glucose networks were affected, including
Figure 1 Effects of TIIA on cell growth and proliferation of AGS
cells. (A) Growth curves show a dosage-dependent pattern of growth
inhibition after TIIA treatment for 72 hr. All TIIA treatment conditions
had significant effects on AGS cell growth (p < 0.0001, Wilcoxon
Signed-Rank Test). Cell indexes of AGS cells were measured by
an RTCA DP® system, expressed as mean ± SD of three replications.
(B) Colonies of AGS cells were stained by crystal violet (purple-colored
dots) after TIIA treatment. Control conditions exhibit many colonies,
while IC50 TIIA conditions have produced almost no colonies. (C) TIIA
significantly reduces the number of AGS colonies (*p < 0.05, **p < 0.01,
Student’s t-Test) in a dosage-dependent manner. Histogram values are
expressed as mean ± SD from three replications.
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phatidylinositol-3,4,5-triphosphate pathway, Ceramide path-
way, Pentose phosphate pathways and transport, Glucose
pathway, Glycolysis, Gluconeogenesis and glucose trans-
port, and Sucrose metabolism and transport. It has been
known that PI3K, an key enzyme of phosphatidylinositol-
4,5-diphosphate and phosphatidylinositol-3,4,5-triphosphate
pathways, increases glycolysis in cancer cells [18]. Based
on these results, we propose that TIIA-regulated pathways
involving in the enriched Glycolysis, Gluconeogenesis and
glucose transport network (Figure 2C).Moreover, a total of 2,761 differentially expressed genes
(DEGs) were considered that have different expression be-
tween control and TIIA treatment samples (FDR ≤ 0.001
and |log2(fold-change)|≥ 1) (Additional files 1 and 2). Among
these, 1,010 genes were up-regulated and 1,751 genes were
down-regulated by TIIA. MetaCore networks analysis of
DEGs reveals significantly enriched biological processes
that frequently occur in gastric cancer cells with TIIA
treatment. As shown in Table 1 and Additional file 3,
major bio-functional networks were in correspondence
with the enrichment analysis of integrative transcriptome
(Figure 2A), such as Cell cycle_G2-M, DNA damage_DBS
repair, Apoptotic nucleus, Cytoskeleton_Intermediate
filaments.
Proteomic expression profiling of TIIA-treated gastric cells
To further elucidate cellular mechanism and molecular
function, we performed iTRAQ-based proteomics ana-
lysis to assess the protein expression profiles in AGS
cells with TIIA treatment. Equal amounts of peptides
collected from control samples or TIIA-treated samples
were labeled with iTRAQ reagents, respectively, and
used for replication (control samples labeled by 114 or
115; TIIA-treated samples labeled by 116 or 117). All la-
beled peptides were mixed and analyzed by liquid chro-
matography coupled with tandem mass spectrometry
(LC-MS/MS). A total of 102 differentially expressed pro-
teins were identified with a false discovery rate (FDR) of
3.94%; annotated MS/MS spectra are collected in Table 2
and Additional file 4. There were 100% of identified pep-
tides that were labeled with iTRAQ reagents. The inten-
sity levels of iTRAQ signals distribution plots show that
positive correlation among our treatments (Additional
file 5), suggesting that labeled samples with a high repro-
ducibility were present in this study.
In order to validate iTRAQ data, we evaluated certain
identified protein expression patterns (fold change > 1.5
or < 0.65) by Western blot analysis, including prote-
asome subunit β type-3 (PSMB3), 40S ribosomal protein
S2 (RS2) and glucose-6-phosphate isomerase (G6PI). In
our MS/MS spectra, PSMB3 (Figure 3A), RS2 (Figure 3B)
and G6PI (Figure 3C) displayed a high intensity across
different samples. After western blotting analysis, PSMB3
can be detected to be significantly up-regulated (fold
change = 1.45, p < 0.05) whereas RS2 (fold change = 0.49,
p < 0.01) and G6PI (fold change = 0.1, p < 0.01) were sig-
nificantly down-regulated (Figure 3D). As our results, ex-
pression patterns of PSMB3, RS2 and G6PI correspond
with our iTRAQ data for those proteins, suggesting the
consistence between iTRAQ and western blotting data.
TIIA suppresses glucose metabolism of gastric cancer cells
To delineate the mechanism of TIIA in gastric cancer cells,
we compared our quantitative proteomics and transcriptomics
Figure 2 Enrichment analyses of the biological processes of TIIA-regulated genes. Analysis of TIIA-regulated genes with MetaCore software
enriched the biological processes. (A) Classification of all identified genes collected from RNA-seq into process networks. (B) Classification of all
identified genes collected from RNA-seq into metabolic networks. (C) The “Glycolysis, gluconeogenesis and glucose transport” network built from
(B). Enzymes expressed at RNA-seq and iTRAQ are circled in red for clarity. Significance calculated by MetaCore was plotted as the negative log
of the p value.
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proteins involved in glycolysis, the cell cycle, apoptosis,
DNA damage and cytoskeleton rearrangement. As shown
in Figure 2C, five proteins (PGAM4, ENO1, LDHA, LDHB
and G6PI) were identified at both the protein and tran-
scription level. After western blotting analysis, we found
that the protein expression of G6PI and LDHB was down-
regulated by TIIA, and ENO1 was not changed (Figures 3D
and 4A). Because G6PI and LDHB are important en-
zymes in glycolysis and gluconeogenesis, respectively, we
further examined if TIIA can regulate other proteins re-
lated to glucose metabolism, such as aldolase C (ALDOC),
malate dehydrogenase 1 (MDH1), phosphoenolpyruvateTable 1 Enrichment analysis of RNA-seq-identified DEGs by M
Function description
(number of genes)
P-value Differentially expressed genes (DE
Cell cycle_G2-M (75) 9.611E-13 Cyclin G, DNMT3B, Ubiquitin, TOP2 be
Histone H3, HUS1, Miz-1, CDC25C, PTC
14-3-3 sigma, EGFR, GTSE1, ATM, MAD
PDGF-A, LATS2, Lamin B, ETS2, GADD4
CAP-D2/D3, KNSL1, Aurora-B, CDC25A,
receptor, ATR, Cyclin B1, Emi1, c-Myc, C
Histone H1, CDK1 (p34), CDK7, CDC27
DNA damage_DBS
repair (44)
1.260E-08 Ubiquitin, TOP2 beta, Tip60, Sirtuin, M
HMGB1, BLM, FANCD2, RAD54B, RAD
Histone H2AX, SMC5, PP2A regulator
DNA polymerase eta, FANCM, PIR51,
Apoptosis_Apoptotic
nucleus (49)
3.077E-06 Tip60, NRIF3, NF-kB2 (p100), DNA po
TIA-1, Separase, Histone H3, ROCK2, C
Histone H2B, IRF5, DOCK1, DNA ligas
beta, Clusterin, DFF40 (CAD), PHAP1
P53DINP1a, Bcl-6, Bard1, APP-BP1, Ni
Cytoskeleton_Intermediate
filaments (30)
4.660E-06 Plectin 1, Tubulin beta, Keratin 17, BPA
Keratin 19, Keratin 8/18, Lamin B1, 14-
light chain, Plakophilin 2, Actin, Fimbricarboxykinase 2 (PCK2) and phosphoglycerate kinase 1
(PGK1), which are involved in gluconeogenesis. ALDOC
and PCK2 were also identified in our transcriptomics
data (Additional file 2). MDH1, which reduces oxalo-
acetate to malate in the mitochondria, was downregu-
lated by TIIA. PCK2, which converts oxaloacetate to
phosphoenolpyruvate, was up-regulated by TIIA (Figure 4B).
The transformation of oncogenes, such as p53 and
AKT, is also involved in the glucose metabolism
switch in cancer cells [18]. We found that p53 in-
creased and AKT decreased in gastric cancer cells fol-
lowing TIIA treatment (Figure 4C). Additionally, TIIA
treatment significantly decreased the intracellular ATPetaCore software
Gs)
ta, ANAPC4, Condensin, UBC, Brca1, Cyclin B, PDGF-B, Cyclin B2, Brca2,
H1, TRF1, Cyclin A2, BLM, CAP-G, PLK4 (STK18), FANCD2, CAP-G/G2,
2a, FOXM1, Lamin B1, GADD45 beta, 14-3-3, BUBR1, TOP2 alpha, CAP-H/H2,
5 alpha, CAP-C, Cyclin A, CNAP1, Rad50, Cyclin G2, DNMT1, Skp2/TrCP/FBXW,
SKP2, DNMT3A, TOP2, PDGF-R-alpha, Dynamin, p21, BUB1, BRRN1, PDGF
laspin, Aurora-A, CDC25, ATRIP, PKA-cat (cAMP-dependent), CAP-E,
RE11, Brca1, BRIP1, Brca2, MeCP2, Histone H3, MRN complex, C1D,
54L, SMC6, ATM, DNA ligase IV, DNA-PK, NEK1, TOP2 alpha, FANCA,
y, Rad50, ChAF1 subunit B, XRCC2, FANCL, TOP2, Sirtuin6, ATR, PSF,
Nibrin, HMG1,2, WRN, ATRIP, Histone H4, p53BP1
lymerase kappa, RelA (p65 NF-kB subunit), Brca1, PARP-1, Tubulin alpha,
aspase-6, BLM, FANCD2, iASPP, C/EBPbeta, Granzyme B, IEX1, ATM,
e IV, FOXO3A, DNA-PK, c-Myb, c-Jun, Protein p8, Lamin B1, GADD45
(pp32), Lamin B, UBE1C, GADD45 alpha, Axin1, NF-kB, p21, ATR,
brin, XPD, Perforin, Histone H1
G2, Desmin, PPL(periplakin), ROCK, Tubulin alpha, SYNE2, ROCK2, Keratin 18,
3-3, Lamin B, Keratin 8, Nestin, Keratin 6A, BPAG1, TMPOA, TMPOB, Kinesin
n, Peripherin, CDK1 (p34), Tubulin (in microtubules), Nesprin 1
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1 Glycolysis P11166 Solute carrier family 2, facilitated
glucose transporter member 1
SLC2A1 72 2 3 1.273 1.573
2 Glycolysis Q8N0Y7 Probable phosphoglycerate
mutase 4
PGAM4 40 1 5.5 1.057 0.309
3 Glycolysis P06733 Alpha-enolase ENO1 720 15 46.8 0.947 0.754
4 Glycolysis P00338 L-lactate dehydrogenase A chain LDHA 283 6 29.2 0.901 0.352
5 Glycolysis P04406 Glyceraldehyde-3-phosphate
dehydrogenase
GAPDH 813 14 55.2 0.823 0.934
6 Glycolysis P07195 L-lactate dehydrogenase B chain LDHB 274 9 29 0.736 0.553
7 Glycolysis O60701 UDP-glucose 6-dehydrogenase UGDH 49 1 4.3 1.001 1.938
8 Glycolysis P06744 Glucose-6-phosphate isomerase GPI 83 1 7.3 0.525 0.824
9 ATP metabolic process P55072 Transitional endoplasmic
reticulum ATPase
VCP 129 4 7.3 0.888 0.661
10 ATP metabolic process P04075 Fructose-bisphosphate aldolase A ALDOA 196 5 30.5 0.804 1.284
11 Protein folding P14625 Endoplasmin HSP90B1 67 1 8.7 1.685 0.738
12 Protein folding P60709 Actin, cytoplasmic 1 ACTB 1161 30 47.2 1.129 0.795
13 Protein folding P62937 Peptidyl-prolyl cis-trans
isomerase A
PPIA 242 6 42.4 1.050 0.640
14 Protein folding P23284 Peptidyl-prolyl cis-trans
isomerase B
PPIB 69 2 11.6 1.084 0.988
15 Protein folding P10809 60 kDa heat shock protein,
mitochondrial
HSPD1 522 7 21.6 1.011 0.724
16 Protein folding P07900 Heat shock protein HSP 90-alpha HSP90AA1 614 7 27.7 0.991 0.572
17 Protein folding P38646 Stress-70 protein, mitochondrial HSPA9 71 1 4.1 1.037 0.946
18 Protein folding P11142 Heat shock cognate 71 kDa
protein
HSPA8 728 18 43.7 0.898 0.804
19 Protein folding P50991 T-complex protein 1 subunit
delta
CCT4 55 1 4.5 0.890 0.883
20 Protein folding P49368 T-complex protein 1 subunit
gamma
CCT3 56 1 4.8 1.119 0.876
21 Protein folding P50454 Serpin H1 SERPINH1 43 1 7.9 0.870 0.568
22 Protein folding Q99832 T-complex protein 1 subunit eta CCT7 38 1 7.7 0.896 0.812
23 Protein folding Q15084 Protein disulfide-isomerase A6 PDIA6 44 1 3.4 0.910 0.876
24 Protein folding P08238 Heat shock protein HSP 90-beta HSP90AB1 549 5 32.6 0.783 0.738
25 DNA damage response Q96QE3 ATPase family AAA
domain-containing protein
ATAD5 44 1 3.4 2.004 0.307
26 DNA damage response P49720 Proteasome subunit beta type-3 PSMB3 105 1 8.8 1.799 0.765
27 DNA damage response P62979 Ubiquitin-40S ribosomal
protein S27a
RS27A 46 1 21.2 1.115 NA
28 DNA damage response Q96QV6 Histone H2A type 1-A HIST1H2AA 205 1 40.5 1.006 NA
29 Cell proliferation Q06830 Peroxiredoxin-1 PRDX1 114 3 31.2 1.098 0.987
30 Cell proliferation P22392 Nucleoside diphosphate kinase B NME2 142 5 47.4 0.924 NA
31 Cell cycle P85299 Proline-rich protein 5 SMR3A 39 1 1.8 1.048 NA
32 G2/M transition of
mitotic cell cycle
P07437 Tubulin beta chain TUBB 660 5 31.8 0.927 0.508
33 Apoptotic process P02545 Prelamin-A/C LMNA 56 2 5.9 1.585 1.457
34 Apoptotic process P23528 Cofilin-1 CFL1 101 1 17.5 1.503 0.735
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35 Apoptotic process P05783 Keratin, type I cytoskeletal 18 KRT18 350 8 36 1.327 2.884
36 Apoptotic process P04264 Keratin, type II cytoskeletal 1 KRT1 1877 38 10.7 1.088 NA
37 Apoptotic process O43707 Alpha-actinin-4 ACTN4 324 10 14.3 1.054 1.560
38 Apoptotic process P61978 Heterogeneous nuclear
ribonucleoprotein K
HNRNPK 221 5 16.6 0.938 0.760
39 Apoptotic process P30101 Protein disulfide-isomerase A3 PDIA3 40 1 9.7 0.702 0.889
40 Apoptotic process P11021 78 kDa glucose-regulated protein HSPA5 191 3 22.3 0.633 1.859
41 Angiogenesis P19338 Nucleolin NCL 242 6 20.4 1.242 0.504
42 Angiogenesis P07355 Annexin A2 ANXA2 412 14 51.9 1.217 1.692
43 Cytoskeleton organization P15311 Ezrin EZR 129 4 17.6 1.377 2.328
44 Cytoskeleton organization P08727 Keratin, type I cytoskeletal 19 KRT19 404 3 39.3 1.329 2.486
45 Cytoskeleton organization P05787 Keratin, type II cytoskeletal 8 KRT8 813 19 52 1.317 2.486
46 Cytoskeleton organization P07737 Profilin-1 PFN1 281 5 34.3 0.923 0.696
47 Actin crosslink formation P21333 Filamin-A FLNA 64 1 2.2 1.055 1.644
48 Microtubule cytoskeleton
organization
Q9BQE3 Tubulin alpha-1C chain TUBA1C 1208 23 45.7 0.869 0.717
49 DNA repair P06748 Nucleophosmin NPM1 145 3 21.1 0.973 0.785
50 DNA ligation P12956 X-ray repair cross-
complementing protein 6
XRCC6 76 2 4.4 0.841 0.746
51 DNA repair Q13263 Transcription intermediary
factor 1-beta
TRIM28 68 2 4.8 1.021 0.841
52 DNA replication P55209 Nucleosome assembly
protein 1-like 1
NAP1L1 61 1 7.4 0.913 0.895
53 DNA replication Q01105 Protein SET SET 77 1 3.4 0.826 0.613
54 Nucleosome assembly P04908 Histone H2A type 1-C HIST1H2AB 175 2 37.7 1.166 NA
55 Nucleosome assembly Q99879 Histone H2B type 1-M HIST1H2BM 355 9 55.6 1.073 NA
56 Nucleosome assembly Q16695 Histone H3.1 t HIST3H3 95 5 35.3 0.991 NA
57 Nucleosome assembly P62805 Histone H4 HIST2H4A 406 14 51.5 0.991 NA
58 Translational elongation P46783 40S ribosomal protein S10 RPS10 82 2 5.5 1.862 1.066
59 Translational elongation P46777 60S ribosomal protein L5 RPL5 36 1 4.7 1.389 1.106
60 Translational elongation P08865 40S ribosomal protein SA RPSA 61 1 14.6 1.243 1.296
61 Translational elongation P62277 40S ribosomal protein S13 RPS13 95 2 23.2 1.014 1.479
62 Translational elongation P61313 60S ribosomal protein L15 RPL15 53 1 5.9 0.983 1.129
63 Translational elongation P32969 60S ribosomal protein L9 RPL9 78 1 18.8 0.838 1.508
64 Translational elongation P23396 40S ribosomal protein S3 RPS3 69 3 23.9 0.845 1.240
65 Translational elongation P13639 Elongation factor 2 EEF2 451 7 24.1 0.796 2.148
66 Translational elongation P62249 40S ribosomal protein S16 RPS16 65 1 25.3 1.042 1.397
67 Translational elongation P50914 60S ribosomal protein L14 RPL14 80 1 25.6 0.744 1.316
68 Translational elongation P39019 40S ribosomal protein S19 RPS19 76 2 31 0.702 1.710
69 Translational elongation Q02543 60S ribosomal protein L18a RPL18A 50 1 5.1 0.709 1.369
70 Translational elongation P46778 60S ribosomal protein L21 RPL21 58 1 9.4 0.609 1.377
71 Translational elongation P18124 60S ribosomal protein L7 RPL7 58 1 11.3 0.538 1.304
72 Translational elongation P15880 40S ribosomal protein S2 RPS2 38 1 11.3 0.333 1.370
73 RNA metabolic process P55010 Eukaryotic translation initiation
factor 5
EIF5 51 1 3.5 2.675 1.248
74 RNA metabolic process P07910 Heterogeneous nuclear
ribonucleoproteins C1/C2
HNRNPC 158 2 20.3 0.917 0.682
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75 RNA metabolic process O14979 Heterogeneous nuclear
ribonucleoprotein D-like
HNRNPDL 63 2 6.4 0.810 NA
76 RNA metabolic process Q32P51 Heterogeneous nuclear
ribonucleoprotein A1-like 2
HNRNPA1L2 250 7 29.4 0.764 1.117
77 RNA metabolic process P60842 Eukaryotic initiation factor 4A-I EIF4A1 115 2 16.3 0.725 0.595
78 RNA metabolic process P52597 Heterogeneous nuclear
ribonucleoprotein F
HNRNPF 116 2 9.6 0.647 0.699
79 Epidermis development P02533 Keratin, type I cytoskeletal 14 KRT14 266 1 21.4 2.455 0.667
80 Epidermis development P35527 Keratin, type I cytoskeletal 9 KRT9 506 16 26.6 1.072 NA
81 Ectoderm development P04259 Keratin, type II cytoskeletal 6B KRT6B 432 1 23 1.225 22.537
82 Sulfur amino acid
metabolic process
P23526 Adenosylhomocysteinase AHCY 43 1 9.7 1.798 0.967




HNRNPAB 62 1 2.4 1.640 0.543
84 Energy reserve metabolic
process
P05141 ADP/ATP translocase 2 SLC25A5 58 1 5.7 1.412 1.234
85 Embryo development P60174 Triosephosphate isomerase TPI1 63 1 4.5 1.362 0.636
86 NADH metabolic process P40926 Malate dehydrogenase,
mitochondrial
MDH2 46 1 3.3 1.262 1.022
87 GTP catabolic process P68371 Tubulin beta-4B chain TUBB4B 490 2 31 1.216 0.572
88 Cellular membrane
organization
P63104 14-3-3 protein zeta/delta YWHAZ 224 2 34.3 1.208 1.016
89 Muscle contraction P07951 Tropomyosin beta chain TPM2 44 1 16.2 1.418 0.744
90 Activation of MAPKK
activity
P31946 14-3-3 protein beta/alpha YWHAB 188 2 24.8 1.201 0.616
91 Protein export from
nucleus
P63241 Eukaryotic translation initiation
factor 5A-1
EIF5AL1 54 1 7.8 1.105 0.772
92 Keratinization P35908 Keratin, type II cytoskeletal 2
epidermal
KRT2 1260 21 38.2 0.974 NA
93 Cellular response to
calcium ion
P13645 Keratin, type I cytoskeletal 10 KRT10 1903 29 45 0.963 1.831
94 Response to hypoxia P14618 Pyruvate kinase PKM PKM 352 10 26.9 0.918 0.811
95 RNA transport P22626 Heterogeneous nuclear
ribonucleoproteins A2/B1
HNRNPA2B1 199 4 18.7 0.881 0.281
96 Histone mRNA metabolic
process
P62318 Small nuclear ribonucleoprotein
Sm D3
SNRPD3 45 1 11.1 0.931 0.479
97 Positive regulation of
protein phosphorylation
P63244 Guanine nucleotide-binding
protein subunit beta-2-like 1
GNB2L1 68 1 7.9 0.860 1.189
98 GTP catabolic process P68104 Elongation factor 1-alpha 1 EEF1A1 543 18 34 0.859 1.596
99 Response to virus P26641 Elongation factor 1-gamma EEF1G 195 4 9.6 0.763 1.257
100 Cilium assembly Q15051 IQ calmodulin-binding
motif-containing protein 1
IQCB1 41 1 2 0.759 1.429
101 Cell redox homeostasis P07237 Protein disulfide-isomerase P4HB 86 3 7.5 0.710 1.076
102 RNA binding Q92804 TATA-binding protein-associated
factor 2 N
TAF15 56 1 2.9 0.614 0.372
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(Figure 4D).
TIIA arrests the cell cycle at the G2/M phase transition
The ability to monitor response to regulation of the cell
cycle is an enriched function from our transcriptomicsdata (Figure 2A and Table 1). We treated AGS cells with
different concentrations of TIIA and measured DNA dis-
tributions by using flow cytometry to detect the cell cycle
distribution of a population of cancer cells. The percent-
age of AGS cells in the G2/M phase increased up to
13.68% above control levels after 5.3 μM TIIA treatment,
Figure 3 MS/MS spectra of peptide and protein levels for PSMB3, RS2 and G6PI. MS/MS spectra of peptides from PSMB3 (A), RS2 (B) and
G6PI (C) are reported along with iTRAQ ion reporter quantification. Ion, m/z 114 and 115 represent peptides collected from control samples. Ion,
m/z 116 and 117 represent peptides collected from TIIA-treated samples. (D) Protein expression levels of PSMB3, RS2 and G6PI were examined
using western blotting analysis, with β-actin as an internal control. All experiments were repeated three times with independent samples.
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G2/M in a dosage-dependent manner (Figure 5A).
As indicated in Table 1, CDK1, cyclin B1 and Cdc25C
are associated with the cell cycle at the G2/M phase, and
were identified in our transcriptomics data. CDK1 acti-
vation can regulate the progression of the cell cycle from
the G2 to the M phase, which is dependent on coordin-
ation with cyclin B [24,25]. The activation of the CDK1/
cyclin-B complex is maintained through phosphorylation
of Thr161 and dephosphorylation of Thr14 and Tyr15 in
CDK1. Dephosphorylation of Thr14 and Tyr15 in CDK1
is catalyzed by phosphatase Cdc25C, which is considered
a rate-limiting step for the G2 to M phase transition
[24,25]. Previous reports suggest monitoring the alter-
ation of CDK1, cyclin B1, Cdc25C, and phospho-CDK1
(CDK1-Thr161) protein expressions is a useful way to
validate the occurrence of cell cycle arrest at the G2/M
transition [26]. For these reasons, to confirm whether
TIIA induces cell cycle arrest at G2/M in gastric cancer
cells, we treated AGS cells with TIIA at a concentration
of 5.3 μM (IC50), and then measured protein expression
levels using western blotting analysis. Levels of phospho-
CDK1 (CDK1-Thr161), cyclin B1, and Cdc25C were all
reduced in cells treated with TIIA (Figure 5B). Our re-
sults indicate that TIIA treatment induced characteristic
cell cycle arrest at G2/M in AGS cells by altering cyclin
B1 and Cdc25C expression as well as the phosphoryl-
ation of CDK1.TIIA treatment causes apoptosis and reorganization of
actin filaments and microtubules
Our cell cycle analysis also indicated that levels of cells
in the sub-G1 phase were increased 5.5% above control
levels under 5 μM TIIA treatment conditions (Figure 5A).
A significant increase of cells in the sub-G1 phase is
widely accepted as a sign of apoptosis induction [27]. As
our transcriptomics and proteomics data (Figure 2A and
Table 1) show, apoptosis-related genes could be induced
by TIIA. We treated AGS cells at different concentrations
of TIIA and detected the proportions of cells undergoing
apoptosis or necrosis using flow cytometry. Our results
show that the proportion of cells undergoing apoptosis
(including early- and late-phase apoptosis) significantly
increased by 15.3% above control levels under 5.3 μM
TIIA treatment conditions, showing that TIIA induced
apoptosis of AGS cells in a dosage-dependent manner
(Figure 6A).
It is widely understood that reorganization of the cyto-
skeleton, including actin filaments and microtubules,
plays a crucial role in apoptosis [28,29]. Links between
this process and TIIA treatment can be seen in our tran-
scriptomics and proteomics data (Figure 2A and Table 1).
To detect whether the cytoskeletons of AGS cells undergo
reorganization after TIIA exposure, we treated AGS cells
with TIIA at different concentrations, then examined the
consequent distribution of actin filaments and microtu-
bules using immunofluorescence staining. Many cells were
Figure 4 Treatment with TIIA changes the expression of glucose metabolism-related proteins in AGS cells. (A) The expression of
iTRAQ-identified proteins, LDHB and ENO1 was estimated using western blotting. (B) The expression of ALDOC, MDH1, PCK2 and PGK1 in
AGS cells treated with TIIA was estimated using western blotting. The levels of (C) tumor suppressor gene, p53, and the oncogene AKT,
and (D) intracellular ATP, were examined in AGS cells treated with TIIA. β-actin was used as an internal control.
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ment (Figure 6B). Actin filaments under TIIA treatment
became more condensed, especially at the cell periphery,
and underwent crumbling. On the other hand, microtu-
bules aggregated to become thick bundles, and were dis-
tributed along nuclear fragmentation sites with condensed
chromatin (Figure 6B). These kinds of cytoskeletal reorga-
nizations, combined with nuclear fragmentation, are all
characteristic of apoptosis [2,28-30], showing that TIIA in-
duced cytoskeleton reorganization arising from apoptosis
in AGS cells.
TIIA triggers γ-H2AX nuclear foci in response to DNA
double strand breaks
Based on our previous results, TIIA could induce DNA
damage in gastric cancer cells (Figure 2A and Table 1).
DNA damage, including double strand breaks (DSB),
often leads to genetic instability; proper cellular responses
to DNA damage are crucial for cell function and survival
[31,32]. Previous studies have shown that phosphorylation
of the histone variant H2AX, producing γ-H2AX atnuclear foci, plays an important role in the DNA damage
response triggered by DSB [33,34]. The change in H2AX
levels was also apparent in our data (Table 1). To examine
whether TIIA triggers DNA damage in gastric cancer
cells, we treated AGS cells with different levels of TIIA
to examine the subsequent localization of γ-H2AX using
immunofluorescence staining. Numerous γ-H2AX foci
were localized in the nuclei of TIIA treated cells, while
γ-H2AX was only represented in a few foci in control
cells (Figure 7A). Increased protein expression of γ-H2AX
was also detected in TIIA-treated cells (Figure 7B). These
results suggest that TIIA triggers DSB, triggering a DNA
damage response in AGS cells.
Discussion
Botanical herbs have been used for disease treatment
and prevention, and as alternative and complementary
therapies [35]. For instance, paclitaxel isolated from one
kind of botanical herb, Taxus brevifolia, has been used
as second-line chemotherapy for advanced or recurrent
gastric cancer [36]. In this study, we treated gastric
Figure 5 TIIA induces cell cycle arrest at the G2/M transition in AGS cells. (A) Flow cytometric analysis shows the distribution of DNA content
in AGS cells after 48 h of TIIA treatment. Cellular DNA was stained by PI and analyzed to quantify the percentage of cells in certain cell cycle phases
using FCS Express 4. The percentage of AGS cells in the G2/M phase transition increases along with increases in TIIA treatment concentrations,
exhibiting a dosage-dependent relationship. The percentage of cells in the sub-G1 phase also increases, from 1.3% (control) to 6.8%
(5.3 μM TIIA), suggesting the occurrence of apoptosis. (B) Protein levels of Phospho-CDK (Thr 161), total CDK, cyclin B1 and Cdc 25C were analyzed
using western blotting. β-actin was used as an internal control.
Figure 6 TIIA induces apoptosis and reorganization of cytoskeleton in AGS cells. (A) AGS cells were treated with different levels of TIIA (1.25 μM
and 5.3 μM). Treated cells were stained with annexin A5 and PI and their apoptotic condition was analyzed by flow cytometry. EA denotes early apoptosis;
LA denotes late apoptosis. (B) Images of AGS cells were obtained by fluorescence microscopy after TIIA treatment for 48 hr. Nuclei were stained with DAPI
(blue), actin filaments were stained with rhodamine-labeled phalloidin (red), and microtubules were stained with mouse anti-α-tubulin antibody and the
corresponding FITC-conjugated secondary anti-mouse IgG antibody (green). Arrows indicate nuclear fragmentation sites with condensed chromatin.
Microtubules are densely packed at these sites; this condensation is an important step during the apoptotic process [30]. Scale bars represent 10 μm.
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Figure 7 TIIA triggers DNA double-strand breaks in AGS cells. (A) Images of AGS cells were obtained by fluorescence microscopy after 48 hr
of TIIA treatment. Nuclei were stained with DAPI (blue), actin filaments were stained with rhodamine-labeled phalloidin (red), and γ-H2AX were
stained with mouse anti-γ-H2AX antibody and the corresponding FITC-conjugated secondary anti-mouse IgG antibody (green). Each zoomed
panel shows representative γ-H2AX distributions in detail. Scale bars represent 10 μm. (B) Protein expression of γ-H2AX increases under an IC50
dose of TIIA; samples were analyzed by Western blotting with β-actin as internal control. Histogram values for fold change are expressed as
mean ± SD from three independent experiments.
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function by limiting apoptosis or oxidative damage [37].
Recently, many studies have shown that TIIA exhibits
anti-tumor potential [10-16], and that on cancers such as
breast cancer, prostate cancer, and leukemia, it can induce
the mitochondria-dependent apoptosis pathway [38-40].
In MKN45 gastric cancer cells, TIIA was reported to in-
hibit cell growth, induce G2/M cell cycle arrest and apop-
tosis [16,41]. However, few of them actually constructed
possible pathways or mechanisms in gastric cancer.
Genes for glycolysis are overexpressed in 70% of all
human cancers worldwide, including gastric cancer [42].
By comparing our transcriptomics and proteomics data,
we are the first to propose that the transformation of glu-
cose metabolism, glycolysis and gluconeogenesis in gastric
cancer cells is a major biological process that is regulated
by TIIA treatment. An enzyme involved in glycolysis,
G6PI, catalyzes the reversible isomerization of glucose-6-
phosphate to fructose-6-phosphate, and is downregulated
by TIIA [43]. Increased synthesis of G6PI, known as auto-
crine motility factor (AMF), is considered to be a unique
feature of cancer cells, which stimulates cell growth and
contributes to cancer metastasis and malignancy [44-47].
AMF can also down-regulate caspase-9 and Apaf-1,
making cancer cells more resistant to mitochondria-
dependent apoptosis [48]. Previous studies have reported
that TIIA can induce mitochondria-dependent apoptosisby regulating caspase-9 and Apaf-1 in several types of can-
cer [38-40]. In gastric cancer, we also found that TIIA
may induce apoptosis (Figure 6A). Based on our results,
we suggest that TIIA might induce the occurrence of
apoptosis by suppressing G6PI expression, which de-
creases glucose consumption and inhibits glycolysis in
cancer cells.
In gluconeogenesis, expression of LDHB, one of the
subunits of lactate dehydrogenase (LDH), which converts
lactate to pyruvate, was shown to decrease in AGS cells
after TIIA treatment. Pyruvate is the end product of gly-
colysis and contributes to gluconeogenesis, acetyl-CoA
which enters the Krebs (TCA) cycle, lipid synthesis and
nonessential amino acid synthesis for proliferative re-
sponses in tumor cells [17]. Decreased LDHB expression
might enhance negative regulation of the Warburg effect,
which mediates pyruvate into lactate and back in tumor
cells [49]. In mouse immortalized cell lines, LDHB is critical
in the mechanistic target of rapamycin (mTOR) pathway to
induce tumor formation [50]. LDHB is also considered as a
tumor marker that increases in many cancers because it fa-
cilitates tumor growth and cell proliferation [51-53]. Serum
LDH is also considered to be predictors for overall survival
of advanced nasopharyngeal carcinoma patients [54]. In
gastric cancer cells, we suggest that TIIA treatment might
block nutrient supply, which reduces cell survival and pro-
liferation by causing lactate dehydrogenase deficiency.
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pyruvate to phosphoenolpyruvate. In colon cancer, in-
creased MDH levels could enhance glycolysis and lead
to cell proliferation and tumorigenesis [55]. Silencing
PCK2 in colon cancer cells could reduce susceptibility
to preoperative 5-fluorouracil-based radiation therapy
[56] and responses to high glucose levels [57]. In this
study, we found that TIIA treatment can decrease MDH1
expression and increase PCK2 expression (Figure 4B). In-
creased PGK1 in gastric cancer is considered as a bio-
marker of advanced gastric cancer and is followed by
increasing intracellular ATP levels [58]. However, TIIA re-
duced intracellular ATP levels and slightly up-regulated
PGK1, which indicates that some functions of TIIA
are still unclear. Moreover, the oncogene AKT was
down-regulated by TIIA, which can stimulate aerobic
glycolysis in cancer cells [59], suggesting that TIIA has the
potential to be used as chemotherapy for gastric cancer
because of its effectiveness in transforming glucose metab-
olism (Figure 8).
The glucose metabolic switch is associated with the
cell cycle, apoptosis and DNA repair in tumor cells [17].
Our transcriptomics analyses and proteomics data also
showed that TIIA can regulate these functions and their
related proteins, such as PSMB3 and RS2. Previous stud-
ies have shown that the expression of PSMB3 and RS2
is involved the development of cancer [60,61]. PSMB3,
which belongs to the proteasome B-type family, was up-
regulated by TIIA. Proteasomes are necessary for the
DNA damage response, and accumulate at double strand
break sites to recruit other repair proteins [62]. TIIA treat-
ment increased the likelihood of the occurrence of DNA
damage in gastric cancer cells (Figure 7), which might
stimulate cancer cells to increase PSMB3 expression.
Moreover, RS2, as a cancer-related ribosomal protein,
was down-regulated by TIIA. Increased RS2 is present
when p53 mutates, which occurs in cell cycle progres-
sion or apoptosis in response to DNA damage [60]. Ele-
vated expression of p53, cell cycle arrest in the G2/M
phase, apoptosis and cytoskeleton reorganization were
observed in AGS cells following TIIA treatment. DNA
damage is one of the major causes of cell cycle arrest in
the G2/M phase [63]. Cytoskeleton reorganization, in-
cluding the redistribution of actin and microtubules, is a
characteristic of chromatin remodeling during apoptosis
[64]. This has also been observed in cancer cells treated
with clinical anti-cancer drugs, such as etoposide, doxo-
rubicin and taxol [65].
Conclusions
We integrate transcriptomics and proteomics data to un-
cover TIIA-regulated mechanisms in gastric cancer. In
glycolysis and gluconeogenesis, TIIA reduces glucose con-
sumption and the production of pyruvate by regulatingG6PI, LDHB, MDH1, PCK2 and PGK1 expression. AKT
decreases and p53 increases in response to apoptosis and
DNA damage in gastric cancer cells following TIIA treat-
ment, while the glucose metabolism switch induced by
the transformation of oncogenes is destroyed (Figure 8).
We suggest that TIIA treatment could cause cell stress,
nutrient deficiency and DNA damage, to induce cycle ar-
rest at the G2/M transition, apoptosis and cytoskeleton
reorganization, all of which would inhibit cell prolifera-
tion. In this study, we provide new insight into the TIIA
regulatory mechanism in gastric cancer cells, so that fu-
ture cancer research can improve therapeutic strategies.
Methods
Cell culture
Human stomach adenocarcinoma AGS (CRL-1739; ATCC)
cells were grown in 90% RPMI 1640 medium (Biological
Industries, Beit Haemek, Israel) supplemented with 10%
fetal bovine serum (Biological Industries). Cells were cul-
tured at 37°C in an incubator with controlled humidified
atmosphere containing 5% CO2. Cells were disaggregated
for subculturing with trypsin plus ethylenediaminetetra-
acetic acid (EDTA), then spun down by centrifugation
at 1200 rpm for 5 min, after which the pellet was re-
suspended in culture medium.
TIIA preparation
Tanshinone IIA powder (T4952; Sigma-Aldrich) was dis-
solved in dimethyl sulfoxide (DMSO) (BioShop), which
was diluted to applicable concentrations for treatment.
Growth curves and IC50 measurement
Growth curves of AGS cells were recorded by an RTCA
DP® system (xCELLigence™; Roche Applied Science &
ACEA Biosciences). Cells were treated with TIIA or 0.1%
DMSO as control for 72 hr after 24 hr of seeding (5,000
cells/well in 96-well E-plates). TIIA treatment concentra-
tions were 0.1 μM, 1 μM, 5.3 μM, and 10 μM; 0.1%
DMSO dissolved in culture medium was used as control.
Each condition was performed in triplicate. The IC50 of
TIIA at 48 hr was calculated with RTCA software 1.2
(xCELLigence™) by using AGS cell growth curves under
TIIA treatments of 0.1 μM, 1 μM, 5.3 μM, and 10 μM.
Colony formation assay
AGS cells were treated with TIIA or 0.1% DMSO control
medium for 5 days after 24 hr of seeding (2,500 cells/well
in 6-well plates). TIIA treatment concentrations were
0.53 μM, 1.06 μM, and 5.3 μM; 0.1% DMSO dissolved in
culture medium was used as control. After treatment, cells
were fixed with methanol for 10 min, stained with 200 μg/mL
crystal violet (Sigma-Aldrich) for 10 min, and then colonies
were counted using AlphaView SA 3.4.0 (ProteinSimple).
Each condition was performed in triplicate.
Figure 8 Schematic representation of TIIA blocking glucose metabolism in gastric cancer cells. In tumor cells, glucose is consumed to
produce ATP, and the glycolytic intermediates are used for biosynthetic pathways. Proto-oncogene, AKT, stimulates glycolysis and the tumor
suppression gene, p53, suppresses glucose metabolism via several pathways. After TIIA treatment, intracellular ATP levels and AKT expression
decreases, and p53 expression increases. In the second step of glycolysis, glucose-6-phosphate isomerase, acting as an enzyme, was down-regulated
by TIIA treatment. We also found that TIIA dysregulates gluconeogenesis by suppressing LDHB and MDH1 expression, and enhancing PCK2 expression.
TIIA promotes the activity of these pathways to suppress cancer cell growth.
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Total RNA was extracted from AGS cells treated with
DMSO (control) or TIIA, using TRIzol reagent (Invitrogen,
USA) according to the manufacturer’s instructions. The
quantity and quality of RNA were checked using an Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA),
and were found to have an RNA Integrity Number (RIN)
value of more than 9. Poly(A) mRNA was isolated with
oligo(dT)-bound magnetic beads and incubated with frag-
mentation buffer to form short RNA fragments. Reverse
transcriptase and random hexamer primers were used to
synthesize the first-strand cDNA, and DNA polymerase I
and RNaseH were used to synthesize the second-strand
cDNA. Double stranded cDNA was end-repaired with T4
DNA polymerase, Klenow fragments, and T4 Polynucleo-
tide Kinase, after which a single “A” base was added, and
the entire sequence was ligated to Illumina sequencing
adapters (Illumina, San Diego, CA). PCR was performed
to amplify the fragments. Using Illumina HiSeqTM 2000
(Illumina), the cDNA library was sequenced on a flow cell
after validation on an Agilent 2100 Bioanalyzer and ABI
StepOnePlus Real-Time PCR System.
After the base calling, the reads with adaptor sequences
and low quality scores were removed. The reads with low
quality scores are defined as the reads with greater than
10% of unknown bases (N) or greater than 50% of lowquality bases which quality values are less than 5. The
reads with high quality scores were mapped to the hu-
man reference genome hg19 assembly using SOAPaligner
in SOAP2 with 2 mismatch allowance [66] and annotated
based on the GENCODE [67]. Read counts for individ-
ual GENCODE genes were subsequently determined
using HTSeq-count (http://www-huber.embl.de/users/
anders/HTSeq), by considering only uniquely mapped
reads. Expression of each individual gene was quantified
by using the Reads Per Kilobase per Million mapped reads
(RPKM) method. The differentially expressed genes were
identified by Poisson distribution model [68]. The se-
quences reported in this study have been deposited in the
Sequence Read Archive database with accession number
SRP049450.
Functional enrichment analysis
We used MetaCore version 6.18 (GeneGo, St. Joseph, MI,
USA) to perform a gene function analysis and to enrich
the functional networks of identified genes collected from
RNA-seq. There were 16,110 of 16,603 identified genes
eligible for network enrichment via GO Processes and
Metabolic Networks analysis. For analysis of differentially
expressed genes (|log2(fold–change)| > 1), 2,717 of 2,761
DEGs were eligible for GO Processes enrichment analysis,
and displayed classified genes (Table 1). All enrichment
Lin et al. BMC Genomics  (2015) 16:41 Page 14 of 17analysis was tested using the p-value threshold p < 0.0001
for the data inputs.
iTRAQ labeling and LC-MS/MS analysis
AGS cells were treated with 5.3 μM (IC50) TIIA or 0.1%
DMSO control medium for 48 hr after 24 hr of seeding
(8 × 104 cells/well in 6-well plates). Cells were harvested
with trypsin/EDTA and then total proteins were ex-
tracted by using lysis buffer (1% SDS (Bioman), 50 mM
Tris–HCl (pH 6.8), 10% glycerol), and 1× protease in-
hibitor (Bioman) and sonication. Proteins were processed
through reduction, alkylation, and gel-assisted trypsin di-
gestion overnight to yield peptides, which were later ex-
tracted from the gels as previous methods [69]. Equal
amounts of peptides from control and TIIA-treated sam-
ples were labeled by different iTRAQ reagents (AB SCIEX;
control samples labeled by 114 or 115; TIIA-treated
samples labeled by 116 or 117) and incubated at room
temperature for 1 hr. Peptides were combined together
and dried with a centrifugal evaporator (CVE-2000;
EYELA). After iTRAQ-labeling, samples were desalted
and analyzed by using a LC-ESI-Q-TOF mass spectrom-
eter (Waters SYNAPT® G2 HDMS; Waters Corp.). Sam-
ples were injected into a 180 mm× 2 cm capillary trap
column and separated by a 75 mm× 25 cm nanoAC-
QUITY UPLC™ 1.7 mm Ethylene Bridged Hybrid C18 col-
umn using a nanoACQUITY Ultra Performance LC™
System (Waters Corp.). The mass spectrometer (MS) was
operated in electrospray ionization sensitivity mode, and
calibrated with a synthetic human [Glu1]-Fibrinopeptide
B solution (1 pmol/ml; Sigma-Aldrich) delivered through
a NanoLockSpray™ source, which was used for accurate
mass measurements. Data was acquired in the data di-
rected analysis (DDA) mode, which included one full MS
scan (m/z 350–1700, 1 s) and three sequential MS/MS
scans (m/z 100–1990. 1.5 s for each scan) on the three
most intense ions present in the full scan mass spectrum.
Protein identification
The peak list resulting from MS/MS spectra was gener-
ated by Mascot Distiller v2.3.2 (Matrix Science, London,
United Kingdom). Data files were searched against the
sequence database (containing 536,789 sequences en-
tries) of the Swiss-Prot human database, using Mascot
search engine v2.3.02 (Matrix Science, London, United
Kingdom). Both the precursor peptide and fragment ion
tolerances were set to ±0.1 Da. The search parameter set-
tings were as follows: allowances for two missed cleavages
from trypsin digestion and variable modifications of
deamidation (NQ), oxidation (M), iTRAQ (N terminal),
iTRAQ (K), and methylthio (C). The peptide charge was
set to Mr, the instrument was set to ESI-QUAD-TOF, and
the decoy database was searched. Mascot search results
were filtered using “Significance threshold” set at p < 0.05and “Ions score or expect cut-off” set at 0.05. To evaluate
the false discovery rate (FDR), we compared a decoy data-
base search against a randomized decoy database created
by Mascot using identical search parameters and valid-
ation criteria. FDR was calculated as D/R × 100%, where D
and R are the number of matches above identity threshold
using the decoy and real databases, respectively. The mass
spectrometry proteomics data have been uploaded to the
ProteomeXchange Consortium [70] via the PRIDE partner
repository with the data set identifier PXD000998 and
DOI 10.6019/PXD000998.
For protein quantitation, signature ions (m/z = 114, 115,
116 and 117) and peptides were detected and analyzed
using Multi-Q software (v1.6.5.4) [71]. Peptides that satis-
fied the following four criteria were subjected to further
analysis. Firstly, the peptide is labeled with iTRAQ tags;
secondly, the peptide has an ion score higher than the
Mascot identity score (p < 0.05); thirdly, the peptide is
nondegenerate (unique); fourthly, the iTRAQ signature
ion peak intensity (ion count) of the peptide is within the
dynamic range (the peak intensity of each iTRAQ signa-
ture ion must be > 0, and the average of the peak inten-
sities of all iTRAQ signature ions must be ≥ 30). Before
quantitation of the expression of each protein, the peak in-
tensity of the iTRAQ signature ion was normalized, as
“Method 1” of our previous study [72]. To determine the
expression ratio of identified proteins in AGS cells from
both the control and the TIIA treatment, the normalized
peptide iTRAQ signal of each identified protein was
summarized, to calculate protein ratios (TIIA treatment/
control).
Western blot analysis
AGS cells were treated with 5.3 μM (IC50) TIIA or 0.1%
DMSO control medium for 48 hr after 24 hr of seeding
(8 × 104 cells/well in 6-well plates). Cells were harvested
with trypsin/EDTA and total proteins were extracted.
Then, proteins from control and TIIA-treated samples
were separated in 12% SDS-PAGE gels, and transferred
onto 0.45 μm PVDF membranes (Millipore) in a Trans-
Blot® SD Semi-Dry Transfer Cell (Bio-Rad) for 50 min at
400 mA. The membrane was blocked for 1 hr at room
temperature in 5% non-fat milk powder/PBS-T (1× PBS,
0.1% Tween 20 (Sigma-Aldrich)) and incubated overnight
at 4°C with blocking buffer containing rabbit monoclo-
nal antibodies to human RS2 (GeneTex; 1:1,000), PSMB3
(GeneTex; 1:1,000), phospho-CDK1 (Santa Cruz; 1:100),
CDK1 (Santa Cruz; 1:100), Cyclin B1 (GeneTax; 1:500),
Cdc25C (GeneTex; 1:1,000), G6PI (GeneTex; 1:1000), ENO1
(GeneTex; 1:2000), MDH1 (GeneTex; 1:500), PGK1 (Gen-
eTex; 1:500), ALDOC (GeneTex; 1:250), PCK2 (GeneTex;
1:1000), LDH-B (GeneTex; 1:100), p53 (Santa Cruz;
1:500) or AKT (Santa Cruz; 1:1000). The membrane was
washed with PBS-T, incubated 1 hr with 5% non-fat milk
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(Sigma-Aldrich) or anti-mouse IgG antibodies (Sigma-
Aldrich, 1:10,000), washed and imaged with enhanced
chemiluminescence (PerkinElmer). The membrane image
was then analyzed by an AutoChemi Image System (UVP)
or exposed to Fuji medical X-ray film, followed by quanti-
fication with AlphaView SA 3.4.0 (ProteinSimple).
Intracellular ATP generation assay
Cells were seeded onto 6-well plates at 8 × 104 cells/well,
and then incubated for 24 h. For the control, 0.1% DMSO
was added to the medium, and for the treatment, 5.3 μM
TIIA was added. After 48 h of drug exposure, the medium
was removed, and then cells were washed twice with PBS.
The levels of intracellular ATP were determined using a
bioluminescent somatic cell assay kit (Sigma-Aldrich),
according to the manufacturer’s instructions, and nor-
malized to protein concentrations. Luminescence was de-
tected using a FlexStation III (Molecular Devices). The
ATP content of each sample was calculated as the average
of the relative light readings and based on the ATP stand-
ard curve.
Flow cytometry
For cell cycle analysis, AGS cells were treated with TIIA
or DMSO as control for 48 hr. TIIA treatment concen-
trations were 0.625 μM, 1.25 μM, 2.5 μM, and 5.3 μM;
0.1% DMSO dissolved in culture medium was used as
control. After treatment, cells were harvested with tryp-
sin/EDTA, fixed with 70% ethanol, then spun down,
after which ethanol was removed. Then each sample was
mixed with RNase A (100 μg/mL), incubated at 37°C for
1 hr, and stained with propidium iodide (PI) (Santa Cruz
Biotechnology, Inc.) at a concentration of 100 μg/mL in
the dark at room temperature for 15 min. For apoptosis
analysis, AGS cells were treated with TIIA or DMSO
control medium for 48 hr after 24 hr of seeding (3.5 × 105
cells in 10-cm plates). TIIA treatment concentrations were
1.25 μM, and 5.3 μM; 0.1% DMSO dissolved in culture
medium was used as control. After treatment, cells were
harvested with trypsin/EDTA, suspended, and counted.
Then each sample was adjusted to a concentration of 106
cells/tube and stained with Annexin V-FITC (Santa Cruz
Biotechnology, Inc.) and PI (Santa Cruz Biotechnology,
Inc.) dissolved in binding buffer (Santa Cruz Biotechnology,
Inc.) in the dark at room temperature for 15 min. Both
cell cycle distribution and apoptotic cells proportion were
then analyzed with a BD FACSCanto II flow cytometer
(BD Biosciences) and FCS Express 4 (BD Biosciences).
Immunofluorescence staining
AGS cells were treated with TIIA or DMSO control
medium for 48 hr after 24 hr of seeding (4 × 104 cells in
6-well plates). TIIA treatment concentrations were 1.25 μMand 5.3 μM, and 0.1% DMSO dissolved in culture medium
was used as control. Cells were washed, fixed with 4%
paraformaldehyde (Sigma-Aldrich) in PBS for 20 min
at 37°C, then permeabilized with 0.25% Triton X-100
(Sigma-Aldrich) in PBS for 10 min at room temperature.
Then cells were incubated with 1% BSA (Bioshop) in PBS
as blocking buffer for 30 min at room temperature, and
labeled with mouse monoclonal antibodies to human
α-tubulin (Millipore; 1:500) or γ-H2AX (Abcam; 1:500)
dissolved in blocking buffer at 4°C overnight. After being
washed with PBS three times, cells were labeled with anti-
mouse FITC-IgG (Millipore; 1:100) and TRITC-conjugated
Phalloidin (Millipore; 1:2000) dissolved in blocking buffer
for 1 hr in the dark at room temperature. Then cells were
washed with PBS three times and mounted with ProLong®
Gold reagent with DAPI (Invitrogen). Images were ac-
quired by using a fluorescence microscope with Leica
HCX FL PLAN 1006/1.25 oil objective, a SPOT camera
(Diagnostic Instruments), and were analyzed with SPOT
Advanced software (Diagnostic Instruments).
Statistical analysis
Data were expressed as mean ± standard deviation (SD)
and analyzed using two-tailed Student’s t-tests. In the
cell proliferation assays, data were analyzed using the
Wilcoxon Signed-Rank test. A P-value of less than 0.05
was taken to indicate statistical significance.Additional files
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